Companies › Neonc Technologies
2 active drug programs in 4 registered trials: 3 Phase 1, 1 Phase 2; Oncology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NEO100 (perillyl alcohol) Monoterpene with potential anti-tumor properties | – | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma; Glioblastoma Multiforme; Pediatric Tumor of CNS | Nov 2026 |
| NEO212 Covalent conjugate of temozolomide and perillyl alcohol (POH-TMZ) | MGMT | Phase 1 | Diffuse Astrocytoma, IDH-Mutant | Feb 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT02704858 | NEO100 (perillyl alcohol) | Phase 1 | Glioblastoma Multiforme | Oncology | Nov 2026 |
| NCT05023018 | NEO100 (perillyl alcohol) | Phase 2 | Residual, Progressive or Recurrent Grade II or III Meningioma | Oncology | Dec 2026 |
| NCT06047379 | NEO212 | Phase 1 | Diffuse Astrocytoma, IDH-Mutant | Oncology | Feb 2027 |
| NCT06357377 | NEO100 (perillyl alcohol) | Phase 1 | Pediatric Tumor of CNS | Oncology | Jun 2027 |
Cash of $6m on 2026-09-30; operating cash outflow about $23m a year; runway about 3 months at that burn, to Jan 2027; 1 of 1 coming phase 2-3 readouts fall inside that runway
Press releases filed as 8-K in the last year:
–
Lantern Pharma Inhibrx Biosciences Immuneering Bio-Path Holdings ALX Oncology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.